Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P19801

UPID:
AOC1_HUMAN

ALTERNATIVE NAMES:
Amiloride-binding protein 1; Amine oxidase copper domain-containing protein 1; Histaminase; Kidney amine oxidase

ALTERNATIVE UPACC:
P19801; C9J690; Q16683; Q16684; Q56II4; Q6GU42

BACKGROUND:
The protein Amiloride-sensitive amine oxidase [copper-containing], with alternative names such as Histaminase and Kidney amine oxidase, catalyzes the breakdown of key substances involved in allergic reactions, immune function, and cell growth. This enzyme's activity is essential for maintaining the balance of biological processes such as tissue differentiation and possibly apoptosis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Amiloride-sensitive amine oxidase [copper-containing] offers a promising pathway for the development of novel therapeutic approaches. Its critical role in degrading substances that influence allergic and immune responses, as well as cell proliferation, positions it as a valuable target in the quest for treatments for immune-related conditions and proliferative diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.